Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019:5:26.
doi: 10.20517/2394-4722.2019.05. Epub 2019 Apr 3.

Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma

Affiliations

Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma

Dustin Rizzieri et al. J Cancer Metastasis Treat. 2019.

Abstract

Metabolism is defined as the collection of complex biochemical processes that living cells use to generate energy and maintain their growth and survival. Metabolism encompasses the synthesis and breakdown of glucose, fatty acids, and amino acids; the generation of energy (ATP); and oxidative phosphorylation. In cancer cells, metabolism can be commandeered to promote tumor growth and cellular proliferation. These alterations in metabolism have emerged as an additional hallmark of various cancers. In this review we focus on metabolic alterations in multiple myeloma (MM) - a malignancy of plasma cells - including derangements in glycolysis, gluconeogenesis, the tricarboxylic acid cycle, oxidative phosphorylation, and fatty acid/amino acid synthesis and degradation. Particular focus is given to metabolic alterations that contribute to myeloma cell growth, proliferation and drug resistance. Finally, novel approaches that target metabolic pathways for the treatment of MM are discussed.

Keywords: Metabolism; alterations; multiple myeloma; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest All authors declared that there are no conflicts of interest.

Figures

Figure 1.
Figure 1.
Summary of the metabolic changes in multiple myeloma cells and in resistant myeloma cells

References

    1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available from: https://seer.cancer.gov/. [Last accessed on 27 Mar 2019]
    1. Latov N Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. .Ann Neurol 1995;37 Suppl l:S32–42. - PubMed
    1. Batuman V The pathogenesis of acute kidney impairment in patients with multiple myeloma. Advances in Chronic Kidney Disease 2012;19:282–6. - PubMed
    1. Zhang J, Sun W, Huang Z, Chen S, Zhong Y, et al. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 2014;12:234. - PMC - PubMed
    1. Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol 2015; doi: 10.1111/ejh.12534. - DOI - PubMed

LinkOut - more resources